# Krascendo 1 (NCT06497556)

> A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06497556
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
- Interventions: Divarasib; Sotorasib; Adagrasib
- Enrollment: 338
- Primary outcome: Progression-Free Survival (PFS)

## Commentary we found

- X threads: 18

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=krascendo-1-nct06497556

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06497556", "email": "<work email>"}; the inbox owner confirms by the emailed link.